Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Single patient of family with positive nucleic acid test of throat swab:Nil
Gathering patients of family with positive nucleic acid test of throat swab:Nil
Mild, severe, critical pneumonia patients groups:Nil
After medication (three groups):Control vs rifximine intervention vs "regular diet" probiotic intervention
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient volunteered to participate and signed the informed consent; 2. 18-65 years old; 3. Patients diagnosed with COVID 19 with diarrhea or positive fecal virus test within 3 months before enrollment; At present, he has at least one of the following gastrointestinal symptoms: abdominal pain, abdominal distension (with a bowel sound, accompanied by increased or frequent belching), and diarrhea. 4. Discontinuation of medication against protocol for abdominal symptoms or diarrhea; 5. During the visit, the patient did not make any major lifestyle changes that might affect the symptoms of diarrhea and abdominal pain (for example, starting a new diet or changing the usual exercise pattern); 6. Within two years, colonoscopy in domestic hospitals at or above the third level reported normal results or abnormal results considered by researchers to have no clinical significance (biopsy is allowed to exclude organic lesions), such as chronic colitis diagnosed by hyperemia and edema, but no erosion ulcer, the diameter of colonic polyps was less than 3mm and the number was less than 5.
Exclusion criteria
Exclusion criteria: 1. Intestinal organic diseases, such as inflammatory bowel disease, intestinal tuberculosis, malabsorption syndrome, celiac disease, lactose intolerance or other organic diseases; 2. Previous history of abdominal and pelvic operations, such as cholecystectomy (except appendectomy, patients without intestinal complications such as intestinal obstruction after cesarean section, and endoscopic treatment of intestinal polyps); 3. Patients with gastrointestinal tract diseases such as chronic pancreatitis, tumor, peptic ulcer, tuberculous peritonitis, chronic liver disease, cirrhosis, etc. (patients with chronic cholecystitis diagnosed by b-ultrasound without typical biliary colic can be included in the group); 4. Other serious systemic diseases, including severe lesions in important organs such as heart, lung and kidney, immune regulatory diseases, metabolic diseases (diabetes mellitus, hyperthyroidism or hypothyroidism) or malignant tumors, reproductive system diseases such as ovarian cyst and endometriosis, etc.; 5. There are significant abnormalities in the laboratory examination, which are considered inappropriate for the researcher to participate in and complete the study: 6. Patients with severe mental illness, or HAMD score >20, or HAMA score >29; 7. In the test, it is impossible to stop the concomitant drugs that affect the gastrointestinal movement and function, such as intestinal microecological preparations), proton pump inhibitors, etc.; 8. Women during pregnancy or lactation or planning to become pregnant during the trial; 9. Less than 3 months after participating in or completing other clinical trials; 10. Researchers think it is not suitable for the candidates.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of microbiota,virology and metabonomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of overall symptom relief;Frequency of defecation;Abdominal distension (with bowel sounds, accompanied by increased gas or frequent belching);Evaluation of urgency of defecation;Use of remedial drugs;Quality of life (IBS-QOL scale); | — |
Countries
China
Contacts
Public ContactXiaohua Hou
Huazhong University of Science and Technology
Outcome results
None listed